Skip to main content
G2GBIO, Inc. logo

G2GBIO, Inc. — Investor Relations & Filings

Ticker · 456160 ISIN · KR7456160001 KO Manufacturing
Open in API
Filings indexed 89 across all filing types
Latest filing 2026-02-23 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 456160

About G2GBIO, Inc.

https://www.g2gbio.com/

G2GBIO, Inc. is a biotechnology company specializing in sustained-release pharmaceuticals through its proprietary drug delivery system platform. The company's core technology, InnoLAMP (Innovative Long-Acting MicroParticle), is used to develop long-acting injectable microspheres that provide a controlled, extended release of therapeutic agents. This platform aims to improve treatment efficacy and patient compliance for chronic diseases by reducing dosing frequency. G2GBIO's research and development pipeline is focused on creating long-acting formulations for conditions including Alzheimer's disease, Type 2 diabetes, schizophrenia, and post-operative pain. The company also develops specialized applications for targeted drug delivery in areas such as oncology.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from G2G Bio, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자 결정). It outlines the issuance of new shares (third-party allocation), the purpose of the funds (facility and operating funds), the conversion price of preferred shares, and the list of investors. This is a formal regulatory filing regarding capital structure changes and share issuance, which falls under the 'Share Issue/Capital Change' category.
2026-02-23 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from a South Korean company, G2G Bio, detailing the issuance of convertible bonds (전환사채권 발행결정). It includes specific terms such as interest rates, conversion price adjustments, put/call options, and a list of investors. This falls under the category of capital and financing updates.
2026-02-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/KRX). This document details the acquisition of shares by an executive (Jeon Gyo-joong) of G2G Bio Co., Ltd. through the exercise of stock options. This falls under the category of 'Director's Dealing' (DIRS), which covers insider trades and changes in share ownership by company directors and executives.
2026-02-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Lee Yong-jin) of G2GBio. This type of filing is a standard regulatory requirement for insiders to disclose changes in their shareholdings, which corresponds to the 'Director's Dealing' category.
2026-02-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This type of filing is a standard regulatory requirement for insiders (directors/executives) to disclose their personal shareholdings and changes therein. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2026-02-13 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory disclosure for insider trading or changes in share ownership by company directors/executives. According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2026-02-13 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.